ProciseDX – Performance Characteristics Of A Fret-Based Immunoassay For Quantitation Of Adalimumab On A Point-Of-Care Instrument System
Adalimumab (ADL; trade name: Humira®) is a recombinant fully human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF) that is approved for reducing signs and symptoms and for induction and maintenance of remission in patients with moderate to severe Crohn’s disease (CD), moderate to severe ulcerative colitis (UC), and pediatric CD or UC
refractory to conventional therapy.1
Measurement of ADL concentrations in human blood has shown utility in optimizing ADL dosing and in managing inflammatory bowel disease (IBD) activity and has demonstrated ability to aid in both UC and CD management. Therapeutic drug monitoring (TDM) of ADL levels among IBD patients has become accepted as the standard of care for the management of IBD.2
Point of care testing of ADL can provide convenience as well as enhanced speed of result turn around for improved patient management.
1Humira® (adalimumab) package insert. North Chicago, IL: AbbVie Inc.
2Vaughn B, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm. Bowel Dis. 2015 Jun; 21(6):1435 42.